MATRAN, Switzerland, November 1, 2016 /PRNewswire/ -- Piramal Imaging S.A. today announced that it has received Shonin (medical device) approval from the Ministry of Health, Labor and Welfare (MHLW) of Japan for Neuraceq Automated Synthesizer Synthera ® (Neuraceq¿¿¿¿¿¿ Synthera ®). The approval, obtained through Piramal Imaging's service partner, SCETI K.K., Tokyo, enables Japanese hospitals and imaging centers access to the equipment needed for on-site manufacturing of the ß-amyloid imaging agent florbetaben 18F, which is approved in the EU, U.S. and South Korea under the brand name Neuraceq™. (Logo: http://photos.prnewswire.com/prnh/20130507/NE09018LOGO ) "The availability of Neuraceq Automated Synthesizer Synthera ® (Neuraceq¿¿¿¿¿¿ Synthera ®) will contribute to further advance public health in Japan by assisting in the diagnosis of Alzheimer's disease and other forms of dementia, a growing concern in the Japanese society," said Dr. Ludger Dinkelborg, Director of the Board, Piramal Imaging. "In addition to expanding the market reach for Neuraceq ™, the Shonin approval for Neuraceq Automated Synthesizer Synthera ® (Neuraceq¿¿¿¿¿¿ Synthera ®) supports our ambition of making this important diagnostic tool available on a global scale to the expanding population facing dementia," Dinkelborg added further. Neuraceq Automated Synthesizer Synthera ® (Neuraceq¿¿¿¿¿¿ Synthera ®) is a medical device manufactured by IBA, SA RadioPharma Solutions, Belgium. MHLW has approved the device, IBA Synthera ® V2, as the manufacturing platform for the in-house production of florbetaben 18F solution for Japanese hospitals. Florbetaben 18F, made on Neuraceq Automated Synthesizer Synthera ® platform (Neuraceq¿¿¿¿¿¿ Synthera ®), is a radioactive diagnostic agent approved in Japan for visualization of brain beta-amyloid plaques in patients with cognitive impairment suspected to have Alzheimer's disease. Florbetaben 18F binds to neuritic beta-amyloid plaques in the human brain, a hallmark characteristic of Alzheimer's disease, a condition that slowly destroys memory and cognitive abilities and currently affects over 46 million people worldwide . Until today, an estimated 20-30% of patients with dementia  have been misdiagnosed and often experience extended diagnostic episodes before receiving a clinical diagnosis. A definitive diagnosis of Alzheimer's disease can only be made after death based on autopsy findings of beta-amyloid plaques and neurofibrillary tangles in the brain. Today, a comprehensive clinical evaluation in combination with in-vivo biomarkers, such as beta-amyloid PET imaging, improves the diagnostic accuracy, allowing for improved patient management. Recently, Piramal Imaging submitted a Summary Technical Document (STED) medical device dossier to the Pharmaceutical and Medical Devices Agency (PMDA) seeking approval for Neuraceq Automated Synthesizer Synthera ® (Neuraceq¿¿¿¿¿¿ Synthera ®). Under the Shonin approval process, Neuraceq Automated Synthesizer Synthera ® (Neuraceq¿¿¿¿¿¿ Synthera ®) is approved as a radioactive-material medical-treatment instrument (category: Equipment 10), with the general designation of radiopharmaceutical synthetic equipment (70009000), Class III. The device is to be distributed to Japanese hospitals by SCETI K.K., Tokyo, who will also train hospital personnel on its use. About Neuraceq™ (florbetaben F18 injection)Indication Neuraceq™ is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline. A negative Neuraceq™ scan indicates sparse to no amyloid neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Neuraceq™ scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq™ is an adjunct to other diagnostic evaluations.